Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel
This article was originally published in The Pink Sheet Daily
Executive Summary
Information Ranbaxy is giving FDA will clear its name, CEO says.
You may also be interested in...
Ranbaxy: Rivals Meddling With Daiichi Sankyo Deal; Congress Enters Fray
CEO Singh goes on TV to say global pharma industry trying to scuttle his deal.
Ranbaxy Denies Fraudulent Conduct Alleged By FDA As Rumors Swirl About Daiichi Deal
Charges stem from 2006 inspection issues Daiichi knew about when it offered to buy a majority stake in the Indian firm.
Pfizer Stalls Generic Lipitor With Ranbaxy Deal
Settlement could give 20 more months of unchallenged U.S. marketing.